Fintel reports that on November 4, 2024, Argus Research upgraded their outlook for AbbVie (NYSE:ABBV) from Hold to Buy.

Thanks to the donation, the facility will be named the AbbVie Foundation Cancer Pavilion when it opens in 2027.

Argus upgraded AbbVie (ABBV) to Buy from Hold with a $220 price target Two of the company’s key immunology products, Skyrizi and Rinvoq, have succeeded Humira as growth engines, with the former having ...

With growth catalysts in place, along with dividend payouts, AbbVie is a good medium to long-term buy. Click here to read an ...

U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

AbbVie (ABBV) stock hits all-time high after beating Q3 earnings expectations with newer immunology drugs outperforming ...

AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...

The biopharmaceutical company agreed to buy Aliada in a deal that adds a potential therapy for Alzheimer’s disease to ...

AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance ...

The community element of this prize makes it highly appealing to enter as it promotes discussions about belonging to ...